Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Glaucoma Therapy Combigan Available In Q4

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm gains FDA approval of treatment to reduce elevated intraocular pressure after three “approvable” letters.

You may also be interested in...



Allergan Adds To Growth Areas With Acquisition Of Eye-Disease Compounds

Deal with UK’s Asterand nets preclinical prostaglandin receptor agonists with potential in glaucoma, other eye conditions.

Allergan Adds To Growth Areas With Acquisition Of Eye-Disease Compounds

Deal with UK’s Asterand nets preclinical prostaglandin receptor agonists with potential in glaucoma, other eye conditions.

Allergan Memantine Filing Delay Anticipated Following Phase III Results

Company awaits results from a second trial evaluating the neuroprotective agent in prevention of vision loss.

Related Content

Topics

UsernamePublicRestriction

Register

PS065292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel